Bevacizumab Approved for Metastatic Renal Cell Carcinoma

Publication
Article
OncologyONCOLOGY Vol 23 No 9
Volume 23
Issue 9

Genentech announced that the US Food and Drug Administration (FDA) has approved bevacizumab (Avastin) plus interferon- alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.

Genentech announced that the US Food and Drug Administration (FDA) has approved bevacizumab (Avastin) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. Kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, 13,000 Americans will die from the disease.

“During the last 5 years, Avastin has been approved by the FDA to treat five different types of cancer,” said Hal Barron, MD, executive vice president, Global Development and chief medical officer, Genentech. “We aim to help more people facing difficult-to-treat cancers and will continue studying Avastin in more than 30 other tumor types.”

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content